更新于：2024-11-08

Interferon alfa-2b/Taurine/Benzocaine

干扰素α-2b/牛磺酸/苯佐卡因

更新于：2024-11-08

概要

概要

基本信息

药物类型

小分子化药、干扰素

别名

Genferon

靶点

IFNAR x Nav1.8

作用机制

IFNAR激动剂(干扰素α/β受体复合体激动剂)、Nav1.8阻滞剂(X型钠通道蛋白α亚基阻滞剂)、免疫刺激剂

治疗领域

感染

在研适应症

乳头状瘤病毒感染

非在研适应症-

原研机构

Biocad Medical, Inc.

在研机构

Biocad Medical, Inc.

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C9H11NO2

InChIKeyBLFLLBZGZJTVJG-UHFFFAOYSA-N

CAS号94-09-7

查看全部结构式(2)

序列信息

Sequence Code 26333714

当前序列信息引自: *****

关联

100 项与干扰素α-2b/牛磺酸/苯佐卡因相关的临床结果

登录后查看更多信息

100 项与干扰素α-2b/牛磺酸/苯佐卡因相关的转化医学

登录后查看更多信息

100 项与干扰素α-2b/牛磺酸/苯佐卡因相关的专利（医药）

登录后查看更多信息

项与干扰素α-2b/牛磺酸/苯佐卡因相关的文献（医药）

2016-12-01·Voenno-meditsinskii zhurnal

[Prolonged interferon papillomavirus infection treatment].

Article

作者: Shperling, L A ; Shperling, N V ; Romanova, E V ; Vengerovskii, A I

Prolonged interferon papillomavirus infection treatment. In patients with recurrent genital HPV caused by human papillomavirus types 6 and 11, the use of genferon suppository according to prolonged scheme (500 000 IU 2 times a day for 10 days and further 500 000 IU 2 times a week for 3 months) in comparison with a short scheme (500 000 IU, 2 times a day for 10 days) is more effective in preventing recurrence of infection due to the normalization, an immune and cytokine status, as well as the elimination of the infectious agent from the affected tissues. Prolongation of the drug use did not cause undesirable side effects. The effectiveness of prolonged treatment regimes is determined by the pharmacological properties genferon components that provide systemic and local effects.

2013-01-01·Eksperimental'naia i klinicheskaia farmakologiia

[Comparative analysis of the effectiveness of antiviral therapy of children with infectious mononucleosis].

Article

作者: Baranova, I P ; Kurmaeva, D Iu

A group of 126 children (4 to 7 years old) with infectious mononucleosis received basic therapy in combination with nonspecific antiviral drugs. The same therapeutic efficiency was observed for cycloferon and genferon light included in complex treatment of infectious mononucleosis in children. The use of cycloferon (10 mg/kg i.m., single daily injection for 10 days) prevents the development of frequent acute respiratory viral infections in the period of convalescence.

2012-01-01·Voprosy onkologii

[Aproaches to immunotherapy in different immunophenotypes of cutaneous basal cell carcinoma].

Article

作者: Petrunin, D D ; Kostalevskaia, A V ; Okovityĭ, S V ; Suchkov, S V

The combination of two immunomodulating agents (genferon derived from exogenous IFN-alpha2b and cycloferon, endogenous IFN inductor) was added to the complex therapy of 60 patients with different cutaneous basal cell carcinoma (CBCC) immunophenotypes. All patients underwent tumor resection, 1-3 days after surgery the patients received immunotropic therapy by focal cycloferon injections (2 ml of 12.5% solution) on days 1, 2, 4, 6, 8 and 10 post-operation with simultaneous genferon therapy via suppositoria (1 000 000 ME) twice a day for 10 days. The therapy was well-tolerated. Essential parameters of immune homeostasis were evaluated before and 3 months after immunotropic therapy. During further observation (for a mean period of 1.8 years) none of the patients displayed any signs of CBCC relapse. The immunological studies results give evidence for correction of immune disturbances characteristic for CBCC patients. This data confirm the effectiveness of immunotropic therapy for relapse prevention and immune disorders correction and allow recommending it for CBCC patients with high relapse risk.

100 项与干扰素α-2b/牛磺酸/苯佐卡因相关的药物交易

登录后查看更多信息